AR061606A1 - SOLID FORMS OF RIMONABANT AND PROCESSES FOR PREPARATION - Google Patents
SOLID FORMS OF RIMONABANT AND PROCESSES FOR PREPARATIONInfo
- Publication number
- AR061606A1 AR061606A1 ARP070102763A ARP070102763A AR061606A1 AR 061606 A1 AR061606 A1 AR 061606A1 AR P070102763 A ARP070102763 A AR P070102763A AR P070102763 A ARP070102763 A AR P070102763A AR 061606 A1 AR061606 A1 AR 061606A1
- Authority
- AR
- Argentina
- Prior art keywords
- rimonabant
- preparation
- solid forms
- processes
- 2theta
- Prior art date
Links
- JZCPYUJPEARBJL-UHFFFAOYSA-N rimonabant Chemical compound CC=1C(C(=O)NN2CCCCC2)=NN(C=2C(=CC(Cl)=CC=2)Cl)C=1C1=CC=C(Cl)C=C1 JZCPYUJPEARBJL-UHFFFAOYSA-N 0.000 title abstract 4
- 229960003015 rimonabant Drugs 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 2
- 238000002360 preparation method Methods 0.000 title abstract 2
- 239000007787 solid Substances 0.000 title abstract 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 2
- 208000008589 Obesity Diseases 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 238000000634 powder X-ray diffraction Methods 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Child & Adolescent Psychology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente se relaciona con formas solidas de rimonabant y rimonabant amorfo y con los procesos de síntesis para la preparacion de los mismos. Tratamiento de la obesidad. Reivindicacion 1: Solvato de etanol de rimonabant, caracterizado porque presenta un patron de difraccion de rayos X de polvo (2theta)(+- 0, 2°) con picos principales a 6, 7, 8, 4, 10, 1, 12, 1, 13, 5, 14, 4, 16, 7, 18, 2, 19, 3, 20, 9 y 21, 8° aproximadamente.This is related to solid forms of rimonabant and amorphous rimonabant and to the synthesis processes for their preparation. Obesity treatment Claim 1: Rimonabant ethanol solvate, characterized in that it has a powder x-ray diffraction pattern (2theta) (+ - 0.2 °) with major peaks at 6, 7, 8, 4, 10, 1, 12, 1, 13, 5, 14, 4, 16, 7, 18, 2, 19, 3, 20, 9 and 21, 8 ° approximately.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US81556406P | 2006-06-22 | 2006-06-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR061606A1 true AR061606A1 (en) | 2008-09-10 |
Family
ID=39230601
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP070102763A AR061606A1 (en) | 2006-06-22 | 2007-06-22 | SOLID FORMS OF RIMONABANT AND PROCESSES FOR PREPARATION |
Country Status (2)
| Country | Link |
|---|---|
| AR (1) | AR061606A1 (en) |
| WO (1) | WO2008038143A2 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008026219A2 (en) * | 2006-09-01 | 2008-03-06 | Hetero Drugs Limited | Novel polymorphs of rimonabant |
| WO2008064615A2 (en) * | 2006-12-01 | 2008-06-05 | Zentiva, A.S. | Crystalline and amorphous forms of rimonabant and processes for obtaining them |
| US20080182877A1 (en) * | 2007-01-05 | 2008-07-31 | Westheim Raymond J H | Rimonabant forms and methods of making the same |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2713225B1 (en) * | 1993-12-02 | 1996-03-01 | Sanofi Sa | Substituted N-piperidino-3-pyrazolecarboxamide. |
| FR2692575B1 (en) * | 1992-06-23 | 1995-06-30 | Sanofi Elf | NOVEL PYRAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. |
| FR2814678B1 (en) * | 2000-10-04 | 2002-12-20 | Aventis Pharma Sa | COMBINATION OF AN ANTAGONIST OF THE CB1 RECEPTOR AND SIBUTRAMINE, THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE FOR THE TREATMENT OF OBESITY |
| FR2831883B1 (en) * | 2001-11-08 | 2004-07-23 | Sanofi Synthelabo | POLYMORPHIC FORM OF RIMONABANT, PROCESS FOR PREPARING THE SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME |
| EP1816125A1 (en) * | 2006-02-02 | 2007-08-08 | Ranbaxy Laboratories, Ltd. | Novel crystalline forms of an antagonist of CB1 cannabinoid receptor and preparation method thereof |
| WO2008026219A2 (en) * | 2006-09-01 | 2008-03-06 | Hetero Drugs Limited | Novel polymorphs of rimonabant |
| EP1953144A1 (en) * | 2007-01-30 | 2008-08-06 | Sandoz AG | Novel polymorphic forms of N-piperidino-5-(4-chlorophenyl)-1-(2, 4-dichlorphenyl)-4-methyl-3-pyrazolecarboxamide |
-
2007
- 2007-06-22 WO PCT/IB2007/003678 patent/WO2008038143A2/en not_active Ceased
- 2007-06-22 AR ARP070102763A patent/AR061606A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2008038143A3 (en) | 2009-02-19 |
| WO2008038143A2 (en) | 2008-04-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR063347A1 (en) | DOCETAXEL CRYSTAL FORMS AND PROCESS FOR PREPARATION | |
| NZ594746A (en) | Inhibitors of iap | |
| TW200709480A (en) | Shaping a phase change layer in a phase change memory cell | |
| IL192944A0 (en) | THE USE OF AN ANTI-EpCAM ANTIBODY FOR THE MANUFACTURE OF A PHARMACEUTICAL COMPOSITION | |
| DK2227243T3 (en) | Pharmaceutical composition for the treatment of obesity related diseases comprising an insulinotropic peptide conjugate | |
| PA8645301A1 (en) | ANTIBODY ANTI-5T4 HUMANIZED AND CONJUGATED ANTIBODY ANTI-5T4 / CALICHEAMICINA | |
| CL2008000831A1 (en) | PROCESSES TO EXTRA EXCESS SOLUBLE PROTEIN AND IMPURITIES FROM CELLULAR LISTS OF STREPTOCOCCUS PNEUMONIAE SEROTYPES USED IN THE PRODUCTION OF PNEUMOCOCAL POLYSACARIDS. | |
| AR048527A1 (en) | CRYSTAL VARIETIES OF BAZEDOXIFEN ACETATE | |
| AR077203A1 (en) | POLYMORPHIC FORM D OF THE BAZEDOXIFEN ACETATE, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN IT METHOD TO PREPARE IT AND USE THE SAME TO TREAT DISEASES MEDIATED BY SELECT MODULATORS OF STROGEN RECEPTORS (SERMS) | |
| EP2046359A4 (en) | SOLUBLE ANTI-INFLAMMATORY FILM | |
| CO6280489A2 (en) | (R) -2- (4-CYCLOPROPANSULPHONYL-PHENYL) -N-PIRAZIN-2-IL-3- (TETRAHYDROPIRAN-4-IL) -PROPIONAMIDE CRYSTALLINE | |
| IL200388A (en) | Antibody, a hybridoma for producing the antibody, a conjugate comprising the antibody, a pharmaceutical composition comprising the antibody and/or the conjugate and uses thereof | |
| NZ599480A (en) | Solid forms comprising (-)-o-desmethylvenlafaxine and uses thereof | |
| ZA200807196B (en) | Processes for the convergent synthesis of calicheamicin derivatives | |
| AP2400A (en) | New process for the synthesis of strontium ranelate and its hydrates. | |
| PT1893224T (en) | Use of plant cell membrane for the treatment of obesity | |
| AR061606A1 (en) | SOLID FORMS OF RIMONABANT AND PROCESSES FOR PREPARATION | |
| AR113893A1 (en) | POLYMORPHES AND SOLID FORMS OF A PYRIMIDINYLAMINE-PIRAZOLE COMPOUND AND PRODUCTION METHODS | |
| ZA200709177B (en) | Combined multi-layered water soluble film and process for producing the same | |
| NI200700175A (en) | PROCESSES FOR THE PREPARATION OF AMINOETOXIBENCIL ALCOHOLS | |
| EA200900936A1 (en) | AMORPHOUS AND CRYSTAL FORMS OF RIVASTYGMIN HYDROTARTRATATE | |
| WO2006085118A3 (en) | Dihydroimidazothiazole derivatives | |
| GB0403808D0 (en) | Films for use as dosage forms | |
| GEP20094854B (en) | Compounds for treating diseases of impaired gastric motility | |
| AR066133A1 (en) | CRYSTALLINE FORMS OF TOPOTECAN CHLORHYDRATE AND PROCESSES TO PREPARE THEM |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |